Recombinant Human Flt-3 Ligand Protein

Formulations:
Catalog # Availability Size / Price Qty
308-FK-005
308-FK-025
308-FK-01M
308-FK-100
308-FK-250
Recombinant Human Flt-3 Ligand Protein Bioactivity
2 Images
Product Details
Citations (46)
FAQs
Supplemental Products
Reviews (1)

Recombinant Human Flt-3 Ligand Protein Summary

Purity
>97%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Endotoxin Level
<0.10 EU per 1 μg of the protein by the LAL method.
Activity
Measured in a cell proliferation assay using BaF3 mouse pro‑B cells transfected with mouse Flt-3. The ED50 for this effect is 0.2-1 ng/mL.
The specific activity of Recombinant Human Flt-3 Ligand is approximately 1.2 x 103 U/μg, which is calibrated against recombinant human
Flt-3 Ligand WHO Standard (NIBSC code: 96/532).
Source
Spodoptera frugiperda, Sf 21 (baculovirus)-derived human Flt-3 Ligand protein
Thr27-Pro185
Accession #
N-terminal Sequence
Analysis
Thr27
Predicted Molecular Mass
17.5 kDa
SDS-PAGE
17-30 kDa, reducing conditions

Product Datasheets

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

308-FK

Formulation Lyophilized from a 0.2 μm filtered solution in Acetonitrile and TFA with BSA as a carrier protein.
Reconstitution Reconstitute at 100 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

308-FK/CF

Formulation Lyophilized from a 0.2 μm filtered solution in Acetonitrile and TFA.
Reconstitution Reconstitute 5 µg vials at 50 µg/mL in sterile PBS. Reconstitute 25 µg or larger vials at 100 µg/mL in sterile PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Data Images

Bioactivity Bioactivity View Larger

Recombinant Human Flt-3 Ligand (Catalog # 308-FK) stimulates cell proliferation in the BaF3 mouse pro-B cell line transfected with mouse Flt-3. The ED50 for this effect is 0.2-1 ng/mL.

SDS-PAGE SDS-PAGE View Larger

1 µg/lane of Recombinant Human Flt-3 Ligand was resolved with SDS-PAGE under reducing (R) conditions and visualized by silver staining, showing major bands at 22‑26 kDa. The multiple bands are due to variable glycosylation of the protein.

Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Background: Flt-3 Ligand

Flt‑3 Ligand, also known as FL, is an alpha -helical cytokine that promotes the differentiation of multiple hematopoietic cell lineages (1-3). Mature human Flt‑3 Ligand consists of a 158 amino acid (aa) extracellular domain (ECD) with a cytokine-like domain and a juxtamembrane tether region, a 21 aa transmembrane segment, and a 30 aa cytoplasmic tail (4-7). Within the ECD, human Flt‑3 Ligand shares 71% and 65% aa sequence identity with mouse and rat Flt‑3 Ligand, respectively. Human and mouse Flt‑3 Ligand show cross-species activity (4-6). Flt‑3 Ligand is expressed as a noncovalently-linked dimer by T cells and bone marrow and thymic fibroblasts (1, 8). Each 36 kDa chain carries approximately 12 kDa of N- and O-linked carbohydrates (8). Alternate splicing and proteolytic cleavage of the transmembrane form can generate a soluble 30 kDa fragment that includes the cytokine domain (4, 8). Alternate splicing of human Flt‑3 Ligand also generates membrane-associated isoforms that contain either a truncated cytoplasmic tail or an 85 aa substitution following the cytokine domain (4, 5, 8). Both transmembrane and soluble Flt‑3 Ligand signal through the tyrosine kinase receptor Flt-3/Flk-2 (3, 4, 6, 7). Flt‑3 Ligand induces the expansion of monocytes and immature dendritic cells as well as early B cell lineage differentiation (2, 9). It synergizes with IL-3, GM-CSF, and SCF to promote the mobilization and myeloid differentiation of hematopoietic stem cells (4-6). It cooperates with IL-2, -6, -7, and -15 to induce NK cell development and with IL-3, -7, and -11 to induce terminal B cell maturation (1, 10). Animal studies also show
Flt‑3 Ligand to reduce the severity of experimentally induced allergic inflammation (11).

References
  1. Wodnar-Filipowicz, A. (2003) News Physiol. Sci. 18:247.
  2. Dong, J. et al. (2002) Cancer Biol. Ther. 1:486.
  3. Gilliland, D.G. and J.D. Griffin (2002) Blood 100:1532.
  4. Hannum, C. et al. (1994) Nature 368:643.
  5. Lyman, S.D. et al. (1994) Blood 83:2795.
  6. Lyman, S.D. et al. (1993) Cell 75:1157.
  7. Savvides, S.N. et al. (2000) Nat. Struct. Biol. 7:486.
  8. McClanahan, T. et al. (1996) Blood 88:3371.
  9. Diener, K.R. et al. (2008) Exp. Hematol. 36:51.
  10. Farag, S.S. and M.A. Caligiuri (2006) Blood Rev. 20:123.
  11. Edwan, J.H. et al. (2004) J. Immunol. 172:5016.
Long Name
fms-like Tyrosine Kinase 3 Ligand
Entrez Gene IDs
2323 (Human); 14256 (Mouse); 493796 (Feline)
Alternate Names
FL; FLG3L; Flt3 ligand; Flt-3 Ligand; Flt3L; FLT3LG; fms-related tyrosine kinase 3 ligand; SL cytokine

Citations for Recombinant Human Flt-3 Ligand Protein

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

46 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. Interconversion between Tumorigenic and Differentiated States in Acute Myeloid Leukemia
    Authors: MD McKenzie, M Ghisi, EP Oxley, S Ngo, L Cimmino, C Esnault, R Liu, JM Salmon, CC Bell, N Ahmed, M Erlichster, MT Witkowski, GJ Liu, M Chopin, A Dakic, E Simankowic, G Pomilio, T Vu, P Krsmanovic, S Su, L Tian, TM Baldwin, DA Zalcenstei, L DiRago, S Wang, D Metcalf, RW Johnstone, BA Croker, GI Lancaster, AJ Murphy, SH Naik, SL Nutt, V Pospisil, T Schroeder, M Wall, MA Dawson, AH Wei, H de Thé, ME Ritchie, J Zuber, RA Dickins
    Cell Stem Cell, 2019;25(2):258-272.e9.
    Species: Human
    Sample Types: Whole Cells
    Applications: Cell Culture
  2. Homologous Recombination-Based Genome Editing by Clade F AAVs Is Inefficient in the Absence of a Targeted DNA Break
    Authors: GL Rogers, HY Chen, H Morales, PM Cannon
    Mol. Ther., 2019;27(10):1726-1736.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  3. Diminished AHR signaling drives human acute myeloid leukemia stem cell maintenance
    Authors: M Ly, S Rentas, A Vujovic, N Wong, S Moreira, J Xu, N Holzapfel, S Bhatia, D Tran, MD Minden, JS Draper, KJ Hope
    Cancer Res., 2019;0(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  4. CRISPR/Cas9 mediated ELANE knockout enables neutrophilic maturation of primary hematopoietic stem and progenitor cells and induced pluripotent stem cells of severe congenital neutropenia patients
    Authors: M Nasri, M Ritter, P Mir, B Dannenmann, N Aghaallaei, D Amend, V Makaryan, Y Xu, B Fletcher, R Bernhard, I Steiert, K Hahnel, J Berger, I Koch, B Sailer, K Hipp, C Zeidler, M Klimiankou, B Bajoghli, DC Dale, K Welte, J Skokowa
    Haematologica, 2019;0(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  5. Therapeutic discovery for marrow failure with MDS predisposition using pluripotent stem cells
    Authors: M Ruiz-Gutie, ÖV Bölükba??, G Alexe, AG Kotini, K Ballotti, CE Joyce, DW Russell, K Stegmaier, K Myers, CD Novina, EP Papapetrou, A Shimamura
    JCI Insight, 2019;5(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Cell Culture
  6. An integration-free iPSC line (MUSIi008-A) derived from a patient with severe hemolytic anemia carrying compound heterozygote mutations in KLF1 gene for disease modeling
    Authors: P Potirat, M Wattanapan, V Viprakasit, P Kheolamai, S Issaragris
    Stem Cell Res, 2019;34(0):101344.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  7. Generation of a human induced pluripotent stem cell line, BRCi001-A, derived from a patient with mucopolysaccharidosis type I
    Authors: M Suga, T Kondo, K Imamura, R Shibukawa, Y Okanishi, Y Sagara, K Tsukita, T Enami, M Furujo, K Saijo, Y Nakamura, M Osawa, MK Saito, S Yamanaka, H Inoue
    Stem Cell Res, 2019;36(0):101406.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  8. High-Efficiency Lentiviral Transduction of Human CD34+ Cells in High-Density Culture with Poloxamer and Prostaglandin E2
    Authors: N Uchida, T Nassehi, CM Drysdale, J Gamer, M Yapundich, S Demirci, JJ Haro-Mora, A Leonard, MM Hsieh, JF Tisdale
    Mol Ther Methods Clin Dev, 2019;13(0):187-196.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  9. A CLK3-HMGA2 Alternative Splicing Axis Impacts Human Hematopoietic Stem Cell Molecular Identity throughout Development
    Authors: M Cesana, MH Guo, D Cacchiarel, L Wahlster, J Barragan, S Doulatov, LT Vo, B Salvatori, C Trapnell, K Clement, P Cahan, KM Tsanov, PM Sousa, B Tazon-Vega, A Bolondi, FM Giorgi, A Califano, JL Rinn, A Meissner, JN Hirschhorn, GQ Daley
    Cell Stem Cell, 2018;22(4):575-588.e7.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  10. Human Cytomegalovirus Encodes a Novel FLT3 Receptor Ligand Necessary for Hematopoietic Cell Differentiation and Viral Reactivation
    Authors: LB Crawford, JH Kim, D Collins-Mc, BJ Lee, I Landais, C Held, JA Nelson, AD Yurochko, P Caposio
    MBio, 2018;9(2):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  11. STK3 is a therapeutic target for a subset of acute myeloid leukemias
    Authors: A Camgoz, M Paszkowski, S Satpathy, M Wermke, MV Hamann, M von Bonin, C Choudhary, S Knapp, F Buchholz
    Oncotarget, 2018;9(39):25458-25473.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  12. Molecular transitions in early progenitors during human cord blood hematopoiesis
    Authors: S Zheng, E Papalexi, A Butler, W Stephenson, R Satija
    Mol. Syst. Biol., 2018;14(3):e8041.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  13. Restricted cell cycle is essential for clonal evolution and therapeutic resistance of pre-leukemic stem cells
    Authors: CS Tremblay, J Saw, SK Chiu, NC Wong, K Tsyganov, S Ghotb, AN Graham, F Yan, AA Guirguis, SE Sonderegge, N Lee, P Kalitsis, J Reynolds, SB Ting, DR Powell, SM Jane, DJ Curtis
    Nat Commun, 2018;9(1):3535.
    Species: Human
    Sample Types: Whole Cells
    Applications: Cell Culture
  14. BRD3/4 inhibition and FLT3-ligand deprivation target pathways that are essential for the survival of human MLL-AF9+ leukemic cells
    Authors: M Carretta, AZ Brouwers-V, M Bosman, SJ Horton, JHA Martens, E Vellenga, JJ Schuringa
    PLoS ONE, 2017;12(12):e0189102.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  15. Stage-Specific Human Induced Pluripotent Stem Cells Map the Progression of Myeloid Transformation to Transplantable Leukemia
    Authors: AG Kotini, CJ Chang, A Chow, H Yuan, TC Ho, T Wang, S Vora, A Solovyov, C Husser, M Olszewska, J Teruya-Fel, D Perumal, VM Klimek, A Spyridonid, RK Rampal, L Silverman, EP Reddy, E Papaemmanu, S Parekh, BD Greenbaum, CS Leslie, MG Kharas, EP Papapetrou
    Cell Stem Cell, 2017;0(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  16. Let-7 microRNA-dependent control of leukotriene signaling regulates the transition of hematopoietic niche in mice
    Authors: X Jiang, JS Hawkins, J Lee, CO Lizama, FL Bos, JP Zape, P Ghatpande, Y Peng, J Louie, G Lagna, AC Zovein, A Hata
    Nat Commun, 2017;8(1):128.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Bioassay
  17. Polycomb protein RING1A limits hematopoietic differentiation in myelodysplastic syndromes
    Authors: A Palau, AK Garz, J Diesch, A Zwick, R Malinverni, V Valero, K Lappin, R Casquero, A Lennartsso, J Zuber, T Navarro, KI Mills, KS Götze, M Buschbeck
    Oncotarget, 2017;8(70):115002-115017.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  18. Targeting of Immune Cells by Dual TLR2/7 Ligands Suppresses Features of Allergic Th2 Immune Responses in Mice
    Authors: J Laiño, A Wangorsch, F Blanco, S Wolfheimer, M Krause, A Flaczyk, TM Möller, M Tsai, S Galli, S Vieths, M Toda, S Scheurer, S Schülke
    J Immunol Res, 2017;2017(0):7983217.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Bioassay
  19. A novel approach for the identification of efficient combination therapies in primary human acute myeloid leukemia specimens
    Authors: I Baccelli, J Krosl, G Boucher, I Boivin, VP Lavallée, J Hébert, S Lemieux, A Marinier, G Sauvageau
    Blood Cancer J, 2017;7(2):e529.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  20. Induced Pluripotent Stem Cell-Derived Natural Killer Cells for Treatment of Ovarian Cancer.
    Authors: Hermanson D, Bendzick L, Pribyl L, McCullar V, Vogel R, Miller J, Geller M, Kaufman D
    Stem Cells, 2016;34(1):93-101.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  21. Pentraxin-2 suppresses c-Jun/AP-1 signaling to inhibit progressive fibrotic disease
    JCI Insight, 2016;1(20):e87446.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  22. Regulated apoptosis of genetically modified hematopoietic stem and progenitor cells via an inducible caspase-9 suicide gene in rhesus macaques.
    Authors: Barese C, Felizardo T, Sellers S, Keyvanfar K, Di Stasi A, Metzger M, Krouse A, Donahue R, Spencer D, Dunbar C
    Stem Cells, 2015;33(1):91-100.
    Species: Primate - Macaca mulatta (Rhesus Macaque)
    Sample Types: Whole Cells
    Applications: Bioassay
  23. SCL, LMO1 and Notch1 reprogram thymocytes into self-renewing cells.
    Authors: Gerby B, Tremblay C, Tremblay M, Rojas-Sutterlin S, Herblot S, Hebert J, Sauvageau G, Lemieux S, Lecuyer E, Veiga D, Hoang T
    PLoS Genet, 2015;10(12):e1004768.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Bioassay
  24. Prospectively Isolated Human Bone Marrow Cell-Derived MSCs Support Primitive Human CD34-Negative Hematopoietic Stem Cells.
    Authors: Matsuoka Y, Nakatsuka R, Sumide K, Kawamura H, Takahashi M, Fujioka T, Uemura Y, Asano H, Sasaki Y, Inoue M, Ogawa H, Takahashi T, Hino M, Sonoda Y
    Stem Cells, 2015;33(5):1554-65.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  25. Functional Characterization of D9, a Novel Deazaneplanocin A (DZNep) Analog, in Targeting Acute Myeloid Leukemia (AML).
    Authors: Jiang X, Lim C, Li Z, Lee P, Yatim S, Guan P, Li J, Zhou J, Pan J, Chng W, Chai C, Yu Q
    PLoS ONE, 2015;10(4):e0122983.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  26. Small-molecule inhibitor of glycogen synthase kinase 3beta 6-Bromoindirubin-3-oxime inhibits hematopoietic regeneration in stem cell recipient mice.
    Authors: Shen S, Xu N, Klamer G, Ko K, Khoo M, Ma D, Moore J, O'Brien T, Dolnikov A
    Stem Cells Dev, 2015;24(6):724-36.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  27. Reversible lineage-specific priming of human embryonic stem cells can be exploited to optimize the yield of differentiated cells.
    Authors: Lee J, Graham M, Collins T, Lee J, Hong S, McNicol A, Shapovalova Z, Bhatia M
    Stem Cells, 2015;33(4):1142-52.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  28. MicroRNA screen of human embryonic stem cell differentiation reveals miR-105 as an enhancer of megakaryopoiesis from adult CD34+ cells.
    Authors: Kamat V, Paluru P, Myint M, French D, Gadue P, Diamond S
    Stem Cells, 2014;32(5):1337-46.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  29. A lack of secretory leukocyte protease inhibitor (SLPI) causes defects in granulocytic differentiation.
    Authors: Klimenkova O, Ellerbeck W, Klimiankou M, Unalan M, Kandabarau S, Gigina A, Hussein K, Zeidler C, Welte K, Skokowa J
    Blood, 2014;123(8):1239-49.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  30. Patient-specific naturally gene-reverted induced pluripotent stem cells in recessive dystrophic epidermolysis bullosa.
    Authors: Tolar J, McGrath J, Xia L, Riddle M, Lees C, Eide C, Keene D, Liu L, Osborn M, Lund T, Blazar B, Wagner J
    J Invest Dermatol, 2014;134(5):1246-54.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  31. Blood stem cell fate regulation by Delta-1-mediated rewiring of IL-6 paracrine signaling.
    Authors: Csaszar, Elizabet, Wang, Weijia, Usenko, Tatiana, Qiao, Wenlian, Delaney, Colleen, Bernstein, Irwin D, Zandstra, Peter W
    Blood, 2014;123(5):650-8.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  32. Repression of BIM mediates survival signaling by MYC and AKT in high-risk T-cell acute lymphoblastic leukemia.
    Authors: Reynolds, C, Roderick, J E, LaBelle, J L, Bird, G, Mathieu, R, Bodaar, K, Colon, D, Pyati, U, Stevenson, K E, Qi, J, Harris, M, Silverman, L B, Sallan, S E, Bradner, J E, Neuberg, D S, Look, A T, Walensky, L D, Kelliher, M A, Gutierrez, A
    Leukemia, 2014;28(9):1819-27.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  33. Clonal tracking of rhesus macaque hematopoiesis highlights a distinct lineage origin for natural killer cells.
    Authors: Wu C, Li B, Lu R, Koelle S, Yang Y, Jares A, Krouse A, Metzger M, Liang F, Lore K, Wu C, Donahue R, Chen I, Weissman I, Dunbar C
    Cell Stem Cell, 2014;14(4):486-99.
  34. Neurokinin-1 receptor signalling impacts bone marrow repopulation efficiency.
    Authors: Berger A, Frelin C, Shah D, Benveniste P, Herrington R, Gerard N, Zuniga-Pflucker J, Iscove N, Paige C
    PLoS ONE, 2013;8(3):U630.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Cell Culture
  35. Epigenetic regulation of NANOG by miR-302 cluster-MBD2 completes induced pluripotent stem cell reprogramming.
    Authors: Lee M, Prasain N, Chae H, Kim Y, Mantel C, Yoder M, Broxmeyer H
    Stem Cells, 2013;31(4):666-81.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  36. Characterization of CD56+ dendritic-like cells: a normal counterpart of blastic plasmacytoid dendritic cell neoplasm?
    Authors: Osaki Y, Yokohama A, Saito A, Tahara K, Yanagisawa K, Ogawa Y, Ishizaki T, Mitsui T, Koiso H, Takizawa M, Uchiumi H, Saitoh T, Handa H, Murakami H, Tsukamoto N, Nojima Y
    PLoS ONE, 2013;8(11):e81722.
    Species: Human
    Sample Types: Whole Cells
    Applications: Cell Culture
  37. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.
    Authors: Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, Peng J, Lin E, Wang Y, Sosman J, Ribas A, Li J, Moffat J, Sutherlin DP, Koeppen H, Merchant M, Neve R, Settleman J
    Nature, 2012;487(7408):505-9.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  38. A novel serum-free monolayer culture for orderly hematopoietic differentiation of human pluripotent cells via mesodermal progenitors.
    Authors: Niwa A, Heike T, Umeda K
    PLoS ONE, 2011;6(7):e22261.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  39. Induced pluripotent stem cells offer new approach to therapy in thalassemia and sickle cell anemia and option in prenatal diagnosis in genetic diseases.
    Authors: Ye L, Chang JC, Lin C, Sun X, Yu J, Kan YW
    Proc. Natl. Acad. Sci. U.S.A., 2009;106(24):9826-30.
  40. Refreezing of cord blood hematopoietic stem cells for allogenic transplantation: in vitro and in vivo validation of a clinical phase I/II protocol in European and Italian Good Manufacturing Practice conditions.
    Authors: Gunetti M, Ferrero I, Rustichelli D, Berger M, Gammaitoni L, Timeus F, Piacibello W, Aglietta M, Fagioli F
    Exp. Hematol., 2008;36(2):235-43.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  41. Isolation and characterization of CD146+ multipotent mesenchymal stromal cells.
    Authors: Sorrentino A, Ferracin M, Castelli G, Biffoni M, Tomaselli G, Baiocchi M, Fatica A, Negrini M, Peschle C, Valtieri M
    Exp. Hematol., 2008;36(8):1035-46.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  42. Thrombopoietin enhances generation of CD34+ cells from human embryonic stem cells.
    Authors: Srivastava AS, Nedelcu E, Esmaeli-Azad B, Mishra R, Carrier E
    Stem Cells, 2007;25(6):1456-61.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  43. Effects of busulfan dose escalation on engraftment of infant rhesus monkey hematopoietic stem cells after gene marking by a lentiviral vector.
    Authors: Kahl CA, Tarantal AF, Lee CI, Jimenez DF, Choi C, Pepper K, Petersen D, Fletcher MD, Leapley AC, Fisher J, Burns TS, Ultsch MN, Dorey FJ, Kohn DB
    Exp. Hematol., 2006;34(3):369-81.
    Species: Primate - Macaca mulatta (Rhesus Macaque)
    Sample Types: Whole Cells
    Applications: Bioassay
  44. Tal1/Scl gene transduction using a lentiviral vector stimulates highly efficient hematopoietic cell differentiation from common marmoset (Callithrix jacchus) embryonic stem cells.
    Authors: Kurita R, Sasaki E, Yokoo T, Hiroyama T, Takasugi K, Imoto H, Izawa K, Dong Y, Hashiguchi T, Soda Y, Maeda T, Suehiro Y, Tanioka Y, Nakazaki Y, Tani K
    Stem Cells, 2006;24(9):2014-22.
    Species: Primate - Callitrix jacchus (Common Marmoset)
    Sample Types: Whole Cells
    Applications: Bioassay
  45. Long-lasting in vitro hematopoiesis derived from primate embryonic stem cells.
    Authors: Hiroyama T, Miharada K, Aoki N, Fujioka T, Sudo K, Danjo I, Nagasawa T, Nakamura Y
    Exp. Hematol., 2006;34(6):760-9.
    Species: Primate - Macaca fascicularis (Crab-eating Monkey or Cynomolgus Macaque)
    Sample Types: Whole Cells
    Applications: Bioassay
  46. The reduction of in vitro radiation-induced Fas-related apoptosis in CD34+ progenitor cells by SCF, FLT-3 ligand, TPO, and IL-3 in combination resulted in CD34+ cell proliferation and differentiation.
    Authors: Drouet M, 49153, Mathieu J, Grenier N, Multon E, Sotto JJ, Herodin F
    Circulating NOD1 Activators and Hematopoietic NOD1 Contribute to Metabolic Inflammation and Insulin Resistance, 1999;17(5):273-85.
    Species: Primate - Papio anubis (Olive Baboon)
    Sample Types: Whole Cells
    Applications: Bioassay

FAQs

No product specific FAQs exist for this product, however you may

View all Proteins and Enzyme FAQs

Reviews for Recombinant Human Flt-3 Ligand Protein

Average Rating: 5 (Based on 1 Review)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%

Have you used Recombinant Human Flt-3 Ligand Protein?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


Recombinant Human Flt-3 Ligand Protein
By Anonymous on 03/28/2018
Application: Stem/Immune cell maintenance or differentiation